ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism: a Phase 0 Trial

Trial Profile

ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism: a Phase 0 Trial

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs ME 344 (Primary) ; Bevacizumab
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Nov 2017 According to MEI Pharma media release, interim results are expected in the first half of 2018.
    • 13 Sep 2017 Planned End Date changed from 1 Jun 2018 to 1 Jan 2019.
    • 13 Sep 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top